Home Three-component synthesis of new o-hydroxyphenyl-substituted pyrazolo[3,4-b]pyridines promoted by FeCl3
Article Open Access

Three-component synthesis of new o-hydroxyphenyl-substituted pyrazolo[3,4-b]pyridines promoted by FeCl3

  • Ling Fan EMAIL logo , Chaochao Yao and Miaomiao Shu
Published/Copyright: March 26, 2016

Abstract

An efficient three-component synthesis of o-hydroxyphenyl-substituted pyrazolo[3,4-b]pyridines from substituted salicylic aldehydes, β-keto esters and 5-aminopyrazoles in the presence of FeCl3 is presented. Newly synthesized compounds were fully characterized by means of 1H NMR, 13C NMR, IR, HRMS and elemental analysis.

Introduction

A large number of natural products and biologically active organic compounds contain the hydroxyl group [1]. Hydroxyl-substituted pyrazolo[3,4-b]pyridine derivatives have received much attention in drug discovery because of their wide biological activities [2]. In recent years, a variety of strategies have been reported for the synthesis of pyrazolo[3,4-b]pyridine derivatives [35] in the presence of various catalysts, such as iodine [6], L-proline [7], InCl3 [8], acetic acid [9, 10] or under microwave/ultrasound irradiation [11, 12], among other approaches [13]. Iron(III) chloride has been widely used as the catalyst in organic synthesis [14]. Herein, we would like to report an efficient one-pot three-component reaction for the synthesis of novel o-hydroxyphenyl-substituted pyrazolo[3,4-b]pyridines from 5-aminopyrazoles, β-keto esters and salicylic aldehydes using FeCl3 as the catalyst.

Results and discussion

In order to optimize conditions for the synthesis of o-hydroxyphenyl-substituted pyrazolo[3,4-b]pyridine 4a, various reaction conditions have been investigated (Table 1). No expected product 4a was observed when commonly used catalysts iodine, acetic acid and L-proline were examined (Table 1, entries 1–3). After screening other catalysts such as InCl3, ZrCl4 and FeCl3, it was found that the best yield of 89% of 4a was obtained by conducting the reaction in ethanol in the presence of 0.2 equiv of FeCl3 (Table 1, entries 4–6). According to the literature reports, a fused coumarin 5a could be formed through transesterification reaction between the hydroxyl and ester group at high temperature [13, 15, 16]. In our hands, transesterification product 5a was not observed probably because of mild reaction conditions. The presence of a small amount of catalyst or lowering the reaction temperature leads to a relatively poor yield (Table 1, entries 7–11). The use of other solvents such as MeOH, MeCN, DMF and toluene also result in a low yield of 4a (Table 1, entries 12–15).

Table 1

Optimization of conditions for the synthesis of 4a.a,b

EntryCatalystSolventTemp (°C)Yieldc (%)
1AcOHEtOHReflux0
2L-prolineEtOHReflux0
3I2EtOHReflux0
4InCl3EtOHRefluxTrace
5ZrCl4EtOHReflux42
6FeCl3EtOHReflux89
7FeCl3EtOHReflux45d
8FeCl3EtOHReflux30e
9FeCl3EtOH6067
10FeCl3EtOH4052
11FeCl3EtOH2530
12FeCl3MeOH6551
13FeCl3MeCN8044
14FeCl3DMF80Trace
15FeCl3Toluene8032

aAll reactions were performed with salicylic aldehyde (1a, 1.0 mmol), ethyl benzoylacetate (2a, 1.0 mmol), 3-methyl-1-phenyl-1H-pyrazol-5-amine (3a, 1.0 mmol) in an appropriate solvent (6 mL) for 3 h.

b0.2 Equiv of catalyst was employed in these reactions unless indicated otherwise.

cIsolated yield.

d0.1 Equiv of catalyst was employed.

e0.05 Equiv of catalyst was employed.

With these results in hand, the synthesis of additional products was investigated under the conditions optimized for the model compound 4a (Scheme 1). The reactions of substituted substrates 2a and 3a bearing electron-donating and electron-withdrawing groups afford the corresponding products 4b–g in good to excellent yields (65–90%). In case when R2 is an alkyl group, products 4h–j are obtained in 70–78% yields. The use of ethyl 4,4,4-trifluoroacetoacetate (2, R = CF3) also gives good results, delivering 4k–n in 70–78% yields. When 1,3-diphenyl-1H-pyrazol-5-amine (3b) was employed, 4o and 4p were isolated in 64% and 57% yields, respectively.

Scheme 1
Scheme 1

Conclusions

An efficient FeCl3-catalyzed three-component reaction for the synthesis of o-hydroxyphenyl-substituted pyrazolo[3,4-b]pyridines from substituted salicylic aldehydes, β-keto esters and 5-aminopyrazoles in refluxing ethanol was developed. This reaction has the advantages of wide substrate scope, mild reaction conditions and good yields.

Experimental

All reagents were commercially available and used without further purification. Solvents were dried and freshly distilled before use. 1H and 13C NMR spectra were recorded in CDCl3 using Bruker AV 300 MHz spectrometers at 300 MHz and 75 MHz, respectively. IR spectra were obtained in KBr pellets using a Nicolet 5700 FT-IR spectrometer. High resolution mass spectra were recorded on a Bruker UltrafleXtreme MALDI TOF/TOF spectrometer. The CHN microanalyses were carried out with a Perkin-Elmer 2400 elemental analyzer. Flash column chromatography was performed on silica gel (200–300 mesh). Melting points were determined using X-4 apparatus and are not corrected.

General procedure for the synthesis of products 4

A mixture of substituted salicylic aldehyde (1, 1.0 mmol), β-keto ester (2, 1.0 mmol), 5-aminopyrazole (3, 1.0 mmol) and FeCl3 (0.2 mmol) was heated in anhydrous ethanol (6 mL) under reflux. After the reaction was completed (3 h, monitored by TLC), the mixture was cooled to room temperature, concentrated and the residue was purified by column chromatography using petroleum ether-ethyl acetate as the eluent.

Ethyl 4-(2-hydroxyphenyl)-3-methyl-1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (4a)

Yellow solid; mp 177–178°C; 1H NMR: δ 8.30 (d, J = 7.9 Hz, 2H), 7.74 (m, 2H), 7.47 (m, 5H), 7.29 (m, 2H), 7.15 (d, J = 6.5 Hz, 1H), 6.97 (m, 2H), 6.30 (s, 1H), 3.89 (m, 2H), 2.07 (s, 3H), 0.79 (t, J = 7.1 Hz, 3H); 13C NMR: δ 169.3, 156.8, 153.3, 150.1, 143.9, 141.1, 139.9, 139.2, 130.7, 130.1, 129.0, 128.8, 128.3, 125.7, 124.0, 122.6, 121.0, 120.5, 116.9, 114.0, 61.8, 13.4, 13.3; IR: ν 3397, 2923, 2857, 2360, 1693, 1457, 1255, 754 cm-1. HRMS. Calcd for C28H24N3O3 [M+H]+: m/z 450.1812. Found: m/z 450.1824. Anal. Calcd for C28H23N3O3: C, 74.82; H, 5.16; N, 9.35. Found: C, 75.06; H, 5.18; N, 9.33.

Ethyl 4-(2-hydroxy-4-methoxyphenyl)-3-methyl-1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (4b)

Yellow solid; mp 291–292°C; 1H NMR: δ 8.31 (d, J = 8.7 Hz, 2H), 7.75 (m, 2H), 7.48 (m, 5H), 7.27 (m, 1H), 7.07 (m, 1H), 6.60 (m, 2H), 6.06 (s, 1H), 3.93 (m, 2H), 3.83 (s, 3H), 2.13 (s, 3H), 0.84 (t, J = 7.1 Hz, 3H); 13C NMR: δ 169.6, 161.8, 156.7, 154.4, 150.1, 144.0, 140.8, 140.0, 139.3, 130.9, 129.0, 128.7, 128.4, 125.7, 124.5, 121.0, 115.0, 114.5, 107.0, 102.7, 61.9, 55.3, 13.7, 13.4; IR: ν 3431, 2359, 1626, 1425, 1162, 1103, 758 cm-1. HRMS. Calcd for C29H26N3O4 [M+H]+: m/z 480.1918. Found: m/z 480.1920. Anal. Calcd for C29H25N3O4: C, 72.64; H, 5.25; N, 8.76. Found: C, 72.83; H, 5.27; N, 8.74.

Ethyl 4-(5-bromo-2-hydroxyphenyl)-3-methyl-1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (4c)

Yellow solid; mp 231–232°C; 1H NMR: δ 8.30 (d, J = 8.7 Hz, 2H), 7.72 (m, 2H), 7.48 (m, 6H), 7.30 (m, 2H), 6.91 (d, J = 8.7 Hz, 1H), 6.25 (s, 1H), 3.89 (m, 2H), 2.12 (s, 3H), 0.85 (t, J = 7.1 Hz, 3H); 13C NMR: δ 169.4, 156.9, 152.6, 150.1, 143.6, 139.8, 139.2, 139.1, 133.5, 132.7, 129.2, 129.1, 128.7, 128.4, 125.9, 124.8, 123.7, 121.1, 119.2, 113.7, 112.6, 62.2, 13.7, 13.3; IR: ν 3398, 1692, 1498, 1409, 1285, 1164, 764 cm-1. HRMS. Calcd for C28H23BrN3O3 [M+H]+: m/z 528.0917. Found: m/z 528.0932. Anal. Calcd for C28H22BrN3O3: C, 63.65; H, 4.20; N, 7.95. Found: C, 63.86; H, 4.21; N, 7.93.

Ethyl 4-(3,5-dibromo-2-hydroxyphenyl)-3-methyl-1,6-diphenyl-1H-pyrazolo[3,4-b] pyridine-5-carboxylate (4d)

Yellow solid; mp 215–216°C; 1H NMR: δ 8.31 (d, J = 8.0 Hz, 2H), 7.75 (m, 3H), 7.49 (m, 5H), 7.32 (m, 2H), 5.99 (s, 1H), 3.94 (m, 2H), 2.16 (s, 3H), 0.88 (t, J = 7.1 Hz, 3H); 13C NMR: δ 168.3, 157.2, 150.0, 149.3, 143.2, 139.9, 139.2, 138.8, 135.1, 132.4, 129.10, 129.05, 128.8, 128.4, 125.9, 125.1, 123.3, 121.0, 113.4, 112.5, 111.8, 61.7, 13.8, 13.4; IR: ν 3375, 2967, 1710, 1563, 1461, 1276, 1238, 1146, 1017, 752, 702 cm-1. HRMS. Calcd for C28H22Br2N3O3 [M+H]+: m/z 608.0004. Found: m/z 608.0018. Anal. Calcd for C28H22Br2N3O3: C, 55.38; H, 3.49; N, 6.92. Found: C, 55.52; H, 3.50; N, 6.90.

Ethyl 4-(5-chloro-2-hydroxyphenyl)-3-methyl-1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (4e)

Yellow solid; mp 207–209°C; 1H NMR: δ 8.31 (d, J = 8.8 Hz, 2H), 7.73 (m, 2H), 7.49 (m, 5H), 7.33 (m, 2H), 7.19 (m, 1H), 7.00 (d, J = 8.7 Hz, 1H), 6.04 (s, 1H), 3.95 (m, 2H), 2.12 (s, 3H), 0.85 (t, J = 7.1 Hz, 3H); 13C NMR: δ 169.3, 156.9, 152.1, 150.1, 143.5, 139.8, 139.2, 130.7, 129.9, 129.2, 129.1, 128.7, 128.4, 125.9, 125.7, 124.4, 123.8, 121.1, 118.9, 113.7, 62.1, 13.7, 13.3; IR: ν 3432, 2925, 1642, 1499, 1284, 1163, 1106, 763 cm-1. HRMS. Calcd for C28H23ClN3O3 [M+H]+: m/z 484.1422. Found: m/z 484.1427. Anal. Calcd for C28H22ClN3O3: C, 69.49; H, 4.58; N, 8.68. Found: C, 69.62; H, 4.59; N, 8.65.

Ethyl 4-(3,5-dichloro-2-hydroxyphenyl)-3-methyl-1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (4f)

Yellow solid; mp 211–213°C; 1H NMR: δ 8.32 (d, J = 8.8 Hz, 2H), 7.75 (m, 2H), 7.49 (m, 6H), 7.30 (d, J = 7.4 Hz, 1H), 7.20 (m, 1H), 5.93 (s, 1H), 3.95 (m, 2H), 2.17 (s, 3H), 0.87 (t, J = 7.1 Hz, 3H); 13C NMR: δ 168.3, 157.2, 150.0, 147.9, 143.2, 139.9, 139.2, 138.7, 129.6, 129.09, 129.05, 128.9, 128.8, 128.4, 125.9, 125.5, 124.8, 123.4, 121.6, 121.0, 113.4, 61.7, 13.7, 13.4; IR: ν: 3424, 2923, 1706, 1640, 1462, 1239, 1150, 1101, 749 cm-1. HRMS. Calcd for C28H22Cl2N3O3 [M+H]+: m/z 518.1033. Found: m/z 518.1047. Anal. Calcd for C28H21Cl2N3O3: C, 64.87; H, 4.08; N, 8.11. Found: C, 65.03; H, 4.10; N, 8.08.

Ethyl 4-(2-hydroxy-5-nitrophenyl)-3-methyl-1,6-diphenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (4g)

Yellow solid; mp 216–217°C; 1H NMR: δ 8.17 (m, 4H), 7.67 (m, 2H), 7.45 (m, 5H), 7.25 (m, 1H), 6.82 (m, 1H), 3.89 (m, 2H), 2.08 (s, 3H), 0.82 (t, J = 7.1 Hz, 3H); 13C NMR: δ 169.7, 159.7, 157.2, 149.9, 143.3, 140.6, 139.6, 138.9, 138.7, 129.2, 129.0, 128.6, 128.4, 126.5, 126.2, 126.1, 123.5, 122.8, 121.2, 116.2, 113.5, 62.3, 13.5, 13.2; IR: ν 3424, 1690, 1587, 1341, 1284, 1161, 1097, 697 cm-1. HRMS. Calcd for C28H23N4O5 [M+H]+: m/z 495.1663. Found: m/z 495.1668. Anal. Calcd for C28H22N4O5: C, 68.01; H, 4.48; N, 11.33. Found: C, 68.19; H, 4.50; N, 11.30.

Ethyl 4-(2-hydroxyphenyl)-3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (4h)

Yellow solid; mp 143–145°C; 1H NMR: δ 8.23 (d, J = 8.7 Hz, 2H), 7.49 (m, 2H), 7.31 (m, 2H), 7.13–7.10 (m, 1H), 6.98 (m, 2H), 5.82 (s, 1H), 4.09 (m, 2H), 2.75 (s, 3H), 2.02 (s, 3H), 0.98 (t, J = 7.1 Hz, 3H); 13C NMR: δ 168.8, 156.4, 153.1, 150.0, 143.8, 140.0, 139.1, 130.5, 129.8, 129.0, 125.8, 124.2, 122.6, 121.2, 120.4, 116.4, 113.5, 61.6, 23.9, 13.5, 13.3; IR ν 3434, 2360, 1715, 1642, 1444, 1376, 1234, 1103, 752 cm-1. HRMS. Calcd for C23H22N3O3 [M+H]+: m/z 388.1656. Found: m/z 388.1664. Anal. Calcd for C23H21N3O3: C, 71.30; H, 5.46; N, 10.85. Found: C, 71.47; H, 5.47; N, 10.83.

Ethyl 6-ethyl-4-(2-hydroxyphenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (4i)

Yellow solid; mp 152–153°C; 1H NMR: δ 8.32 (d, J = 8.2 Hz, 2H), 7.49 (m, 2H), 7.31 (m, 2H), 7.12 (m, 1H), 6.99 (m, 2H), 5.79 (s, 1H), 4.09 (m, 2H), 3.04 (m, 2H), 2.04 (s, 3H), 1.43 (t, J = 7.4 Hz, 3H), 0.99 (t, J = 7.1 Hz, 3H); 13C NMR: δ 168.9, 160.8, 153.1, 150.2, 143.8, 139.7, 139.3, 130.5, 129.9, 128.9, 125.6, 124.0, 122.6, 120.8, 120.4, 116.4, 113.4, 61.6, 29.8, 13.5, 13.3, 13.2; IR: ν 3421, 2972, 1693, 1601, 1443, 1214, 1097, 752 cm-1. HRMS. Calcd for C24H24N3O3 [M+H]+: m/z 402.1812. Found: m/z 402.1812. Anal. Calcd for C24H23N3O3: C, 71.80; H, 5.77; N, 10.47. Found: C, 71.92; H, 5.79; N, 10.44.

Ethyl 4-(2-hydroxyphenyl)-3-methyl-1-phenyl-6-propyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (4j)

Yellow solid; mp 121–125°C; 1H NMR: δ 8.28 (d, J = 7.8 Hz, 2H), 7.47 (m, 2H), 7.25 (m, 2H), 7.09 (d, J = 7.5 Hz, 1H), 6.92 (m, 2H), 6.67 (s, 1H), 4.05 (q, J = 7.4 Hz, 2H), 2.95 (t, J = 7.5 Hz, 2H), 2.03 (s, 3H), 1.92 (m, 2H), 1.04 (t, J = 7.5 Hz, 3H), 0.95 (t, J = 7.1 Hz, 3H); 13C NMR: δ 169.1, 159.8, 153.5, 150.0, 143.9, 140.5, 139.2, 130.3, 129.9, 128.9, 125.5, 124.2, 122.6, 120.9, 120.0, 116.0, 113.4, 61.5, 38.5, 22.4, 14.1, 13.5, 13.3; IR: ν 3442, 2366, 1644, 1447, 1248, 1101, 752 cm-1. HRMS. Calcd for C25H26N3O3 [M+H]+: m/z 416.1969. Found: m/z 416.1978. Anal. Calcd for C25H25N3O3: C, 72.27; H, 6.06; N, 10.11. Found: C, 72.41; H, 6.08; N, 10.09.

Ethyl 4-(2-hydroxyphenyl)-3-methyl-1-phenyl-6-(trifluoromethyl)-1H-pyrazolo[3,4-b] pyridine-5-carboxylate (4k)

Yellow solid; mp 189–190°C; 1H NMR: δ 8.27 (d, J = 8.8 Hz, 2H), 7.53 (m, 2H), 7.36 (m, 2H), 7.14 (m, 1H), 6.99 (m, 2H), 5.98 (s, 3H), 4.13 (q, J = 7.1 Hz, 2H), 2.10 (s, 3H), 1.07 (t, J = 7.1 Hz, 3H); 13C NMR: δ 166.8, 153.3, 148.4, 144.2, 143.3 (2JC-F = 35.0 Hz), 143.1, 142.7, 138.7, 131.2, 129.9, 129.2, 126.3, 122.3, 121.3 (1JC-F = 274.1 Hz), 120.8, 120.5, 117.0, 116.7, 62.5, 29.7, 13.5, 13.3; IR: ν 3429, 2924, 2360, 1711, 1607, 1452, 1189, 751 cm-1. HRMS. Calcd for C23H19F3N3O3 [M+H]+: m/z 442.1373. Found: m/z 442.1384. Anal. Calcd for C23H18F3N3O3: C, 62.58; H, 4.11; N, 9.52. Found: C, 62.74; H, 4.12; N, 9.50.

Ethyl (2-hydroxy-4-methoxyphenyl)-3-methyl-1-phenyl-6-(trifluoromethyl)-1H-pyrazolo [3,4-b]pyridine-5-carboxylate (4l)

Yellow solid; mp 211–212°C; 1H NMR: δ 8.26 (d, J = 7.8 Hz, 2H), 7.53 (m, 2H), 7.31 (m, 1H), 7.03 (d, J = 8.4 Hz, 1H), 6.52 (m, 2H), 6.37 (s, 1H), 4.17 (q, J = 7.1 Hz, 2H), 3.77 (s, 3H), 2.16 (s, 3H), 1.13 (t, J = 7.1 Hz, 3H); 13C NMR: δ 167.1, 162.0, 154.5, 148.4, 144.3, 143.3 (2JC-F = 34.9 Hz), 142.7, 138.7, 130.6, 129.2, 126.3, 122.7, 121.3 (1JC-F = 274.2 Hz), 120.8, 117.5, 113.5, 106.7, 102.3, 62.6, 55.3, 13.6, 13.5; IR: ν 3436, 2994, 2360, 1711, 1622, 1437, 1192, 846, 751 cm-1. HRMS. Calcd for C24H21F3N3O4 [M+H]+: m/z 472.1479. Found: m/z 472.1480. Anal. Calcd for C24H20F3N3O3: C, 63.29; H, 4.43; N, 9.23. Found: C, 63.47; H, 4.44; N, 9.20.

Ethyl 4-(5-bromo-2-hydroxyphenyl)-3-methyl-1-phenyl-6-(trifluoromethyl)-1H-pyrazolo [3,4-b]pyridine-5-carboxylate (4m)

Yellow solid; mp 188–190°C; 1H NMR: δ 8.24 (d, J = 7.8 Hz, 2H), 7.53 (m, 2H), 7.42 (m, 1H), 7.32 (m, 2H), 6.79 (d, J = 8.7 Hz, 1H), 6.64 (s, 1H), 4.20 (q, J = 7.1 Hz, 2H), 2.16 (s, 3H), 1.16 (t, J = 7.1 Hz, 3H); 13C NMR: δ 167.1, 152.8, 148.3, 143.9, 143.3 (2JC-F = 34.9 Hz), 141.0, 138.5, 133.9, 132.3, 129.2, 126.5, 123.0, 121.9, 121.2 (1JC-F = 274.1 Hz), 120.9, 118.5, 116.7, 112.3, 63.0, 13.6, 13.5; IR: ν 3437, 2360, 1709, 1643, 1396, 1265, 1192, 749 cm-1. HRMS. Calcd for C23H18BrF3N3O3 [M+H]+: m/z 520.0478. Found: m/z 520.0475. Anal. Calcd for C23H17BrF3N3O3: C, 53.09; H, 3.29; N, 8.08. Found: C, 53.17; H, 3.30; N, 8.06.

Ethyl 4-(5-chloro-2-hydroxyphenyl)-3-methyl-1-phenyl-6-(trifluoromethyl)-1H-pyrazolo [3,4-b]pyridine-5-carboxylate (4n)

Yellow solid; mp 201–202°C; 1H NMR: δ 8.25 (d, J = 7.8 Hz, 2H), 7.53 (m, 2H), 7.32 (m, 2H), 7.15 (m, 1H), 6.86 (d, J = 8.7 Hz, 1H), 6.52 (s, 1H), 4.20 (q, J = 7.1 Hz, 2H), 2.16 (s, 3H), 1.16 (t, J = 7.1 Hz, 3H); 13C NMR: δ 166.9, 152.2, 148.3, 143.9, 143.3 (2JC-F = 35.0 Hz), 141.0, 138.5, 131.0, 129.5, 129.2, 126.5, 125.4, 122.6, 122.0, 121.2 (1JC-F = 274.1 Hz), 120.9, 118.2, 116.7, 62.9, 13.6, 13.5; IR: ν 3440, 2359, 1707, 1642, 1398, 1192, 1135, 751 cm-1. HRMS. Calcd for C23H18ClF3N3O3 [M+H]+: m/z 476.0983. Found: m/z 476.0983. Anal. Calcd for C23H17ClF3N3O3: C, 58.05; H, 3.60; N, 8.83. Found: C, 58.21; H, 3.61; N, 8.81.

Ethyl 4-(2-hydroxyphenyl)-1,3,6-triphenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (4o)

Yellow solid; mp 309–310°C; 1H NMR: δ 8.42 (d, J = 8.0 Hz, 2H), 7.80 (m, 2H), 7.52 (m, 5H), 7.32 (m, 1H), 7.12 (m, 6H), 6.89 (d, J = 6.7 Hz, 1H), 6.78 (d, J = 8.1 Hz, 1H), 6.64 (m, 1H), 5.96 (s, 1H), 3.89 (q, J = 7.1 Hz, 2H), 0.76 (t, J = 7.1 Hz, 3H); 13C NMR: δ 169.7, 156.9, 153.1, 150.4, 147.2, 141.1, 140.0, 139.3, 132.0, 130.6, 129.15, 129.06, 128.8, 128.7, 128.4, 127.7, 127.5, 126.2, 124.8, 123.3, 121.5, 120.7, 117.5, 112.9, 62.0, 13.2; IR: ν 3406, 2359, 1701, 1644, 1555, 1257, 755 cm-1. HRMS. Calcd for C33H26N3O3 [M+H]+: m/z 512.1969. Found: m/z 512.1970. Anal. Calcd for C33H25N3O3: C, 77.48; H, 4.93; N, 8.21. Found: C, 77.60; H, 4.94; N, 8.20.

Ethyl 4-(2-hydroxyphenyl)-6-methyl-1,3-diphenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (4p)

Yellow solid; mp 311–312°C; 1H NMR: δ 8.36 (d, J = 8.2 Hz, 2H), 7.54 (m, 2H), 7.34 (m, 1H), 7.09 (m, 6H), 6.94 (d, J = 7.5 Hz, 1H), 6.72 (m, 1H), 6.63 (d, J = 8.2 Hz, 1H), 5.26 (s, 1H), 4.09 (q, J = 7.1 Hz, 2H), 2.80 (s, 3H), 0.96 (t, J = 7.1 Hz, 3H); 13C NMR: δ 169.1, 156.2, 152.8, 150.3, 147.0, 139.8, 139.2, 132.0, 130.4, 130.1, 129.0, 128.8, 127.7, 127.4, 126.2, 125.1, 123.0, 121.7, 120.5, 116.4, 112.3, 61.7, 23.9, 13.5; IR: ν 3372, 2359, 1698, 1563, 1500, 1450, 1259, 1142, 755 cm-1. HRMS. Calcd for C28H24N3O3 [M+H]+: m/z 450.1812. Found: m/z 450.1812. Anal. Calcd for C28H23N3O3: C, 74.82; H, 5.16; N, 9.35. Found: C, 74.98; H, 5.17; N, 9.32.


Corresponding author: Ling Fan, Hubei Collaborative Innovation Center for Rare Metal Chemistry, Hubei Key Laboratory of Pollutant Analysis and Reuse Technology, Hubei Normal University, Huangshi 435002, China

Acknowledgments:

We are grateful to the support from the Educational Commission of Hubei Province, China (No. B2015132).

References

[1] Schultz, D. M.; Wolfe, J. P. Catalysis: disguise gets a reaction. Nature2012, 483, 42–43.10.1038/483042aSearch in Google Scholar PubMed

[2] Falcó, J. L.; Lloveras, M.; Buira, I.; Teixidó, J.; Borrell, J. I.; Méndez, E.; Terencio, J.; Palomer, A.; Guglietta, A. Design, synthesis and biological activity of acyl substituted 3-amino-5-methyl-1,4,5,7- tetrahydropyrazolo[3,4-b]pyridin-6-ones as potential hypnotic drugs. Eur. J. Med. Chem. 2005, 40, 1179–1187.10.1016/j.ejmech.2005.06.008Search in Google Scholar PubMed

[3] Allais, C.; Grassot, J. M.; Rodriguez, J.; Constantieux, T. Metal-free multicomponent syntheses of pyridines. Chem. Rev. 2014, 114, 10829–10868.10.1021/cr500099bSearch in Google Scholar PubMed

[4] Dodiya, D. K.; Trivedi, A. R.; Kataria, V. B.; Shah, V. H. Advances in the synthesis of pyrazolo[3,4-b]pyridines. Curr. Org. Chem. 2012, 16, 400–417.10.2174/138527212799499912Search in Google Scholar

[5] Shekarrao, K.; Kaishap, P. P.; Saddanapu, V.; Addlagatta, A.; Gogoi, S.; Boruah, R. C. Microwave-assisted palladium mediated efficient synthesis of pyrazolo[3,4-b]pyridines, pyrazolo[3,4-b]quinolines, pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]quinazolines. RSC Adv. 2014, 4, 24001–24006.10.1039/C4RA02865ASearch in Google Scholar

[6] Pal, S.; Khan, M. N.; Karamthulla, S.; Choudhury, L. H. Molecular iodine catalyzed one-pot multicomponent reactions for the synthesis of dihydrochromeno[4,3-b] pyrazolo[4,3-e] pyridin-6(7H)-ones. RSC Adv. 2013, 3, 15705–15711.10.1039/c3ra41569dSearch in Google Scholar

[7] Gunasekaran, P.; Indumathi, S.; Perumal, S. L-Proline-catalyzed three-component domino reactions in the regioselective synthesis of novel densely functionalized pyrazolo[3,4-b]pyridines. RSC Adv. 2013, 3, 8318–8325.10.1039/c3ra00136aSearch in Google Scholar

[8] Khurana, J. M.; Chaudhary, A.; Nand, B.; Lumb, A. Aqua mediated indium(III) chloride catalyzed synthesis of fused pyrimidines and pyrazoles. Tetrahedron Lett. 2012, 53, 3018–3022.10.1016/j.tetlet.2012.04.001Search in Google Scholar

[9] Jiang, B.; Zhang, G.; Ma, N.; Shi, F.; Tu, S. J.; Kaur, P.; Li, G. G. A new rapid multicomponent domino reaction for the formation of functionalized benzo[h]pyrazolo[3,4-b]quinolines. Org. Biomol. Chem. 2011, 9, 3834–3838.10.1039/c1ob05034fSearch in Google Scholar PubMed

[10] Hao, W. J.; Xu, X. P.; Bai, H. W.; Wang, S. Y.; Ji, S. J. Efficient multicomponent strategy to pentacyclic pyrazole-fused naphtho[1,8-fg]isoquinolines through cleavage of two carbon-carbon bonds. Org. Lett. 2012, 14, 4894–4897.10.1021/ol302452jSearch in Google Scholar PubMed

[11] Bazgir, A.; Ahadi, S.; Ghahremanzadeh, R.; Khavasi, H. R.; Mirzaei, P. Ultrasound-assisted one-pot, three-component synthesis of spiro[indoline-3,4′-pyrazolo [3,4-b]pyridine]-2,6′(1′H)-diones in water. Ultrason. Sonochem. 2010, 17, 447–452.10.1016/j.ultsonch.2009.09.009Search in Google Scholar PubMed

[12] EI-Borai, M. A.; Rizk, H. F.; Abd-Aal, M. F.; EI-Deeb, I. Y. Synthesis of pyrazolo[3,4-b] pyridines under microwave irradiation in multi-component reactions and their antitumor and antimicrobial activities–Part 1. Eur. J. Med. Chem. 2012, 48, 92–96.10.1016/j.ejmech.2011.11.038Search in Google Scholar PubMed

[13] Frolova, L. V.; Malik, I.; Uglinskii, P. Y.; Rogelj, S.; Kornienko, A.; Magedov, I. V. Multicomponent synthesis of 2,3-dihydrochromeno[4,3-d]pyrazolo[3,4-b]pyridine-1, 6-diones: a novel heterocyclic scaffold with antibacterial activity. Tetrahedron Lett. 2011, 52, 6643–6645.10.1016/j.tetlet.2011.10.012Search in Google Scholar PubMed PubMed Central

[14] Bolm, C.; Legros, J.; Le Paih, J.; Zani, L. Iron-catalyzed reactions in organic synthesis. Chem. Rev. 2004, 104, 6217–6254.10.1021/cr040664hSearch in Google Scholar PubMed

[15] Tasior, M.; Poronik, Y. M.; Vakuliuk, O.; Sadowski, B.; Karczewski, M.; Gryko, D. T. V-shaped bis-coumarins: synthesis and optical properties. J. Org. Chem. 2014, 79, 8723–8732.10.1021/jo501565rSearch in Google Scholar PubMed

[16] Chen, J.; Liu, W.; Ma, J.; Xu, H.; Wu, J.; Tang, X.; Fan, Z.; Wang, P. Synthesis and properties of fluorescence dyes: tetracyclic pyrazolo[3,4-b]pyridine-based coumarin chromophores with intramolecular charge transfer character. J. Org. Chem. 2012, 77, 3475–3482.10.1021/jo3002722Search in Google Scholar PubMed


Supplemental Material:

The online version of this article (DOI: 10.1515/hc-2015-0234) offers supplementary material, available to authorized users.


Received: 2016-2-1
Accepted: 2016-3-4
Published Online: 2016-3-26
Published in Print: 2016-4-1

©2016 by De Gruyter

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Downloaded on 15.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/hc-2015-0234/html
Scroll to top button